What we do
Pharmaceuticals with a difference
With a guiding principle of working to improve your health, we deliver pharmaceuticals that make a real difference to people’s health.
AFT is a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories. Our diverse range of products includes both proprietary and in-licensed items, which are available in more than 85 countries worldwide.
We continue to invest in extending our global reach, expanding our product range, and adding new medicines to a research and development portfolio that promises better health outcomes for people around the world.
More about our history here
“At AFT Pharmaceuticals, we remain committed to reinvest into R&D to help people across the world.”
Hartley Atkinson, Founder and Managing Director
AFT in South Africa
AFT Pharmaceuticals SA (Pty) Ltd (‘AFT SA’) was established in early 2025 as part of our global expansion strategy. Jointly owned by AFT Pharmaceuticals (70%) and Edge Pharmaceuticals (30%), AFT SA is able to leverage both companies’ pharmaceutical products as well as Edge’s international expertise in accessing markets.
Following its acquisition of the Hospital Division business of Pharma Dynamics (Pty) Ltd in October 2025, AFT SA now holds a SAHPRA[1] licence and offers a portfolio of more than 30 trusted hospital products. From 2026 onward, it will expand access to a growing range of globally marketed therapeutics for South African hospitals and the wider community.
Join our team
We’re always looking for talented people, please have a look at the careers we currently have available.
Social responsibility
We don’t just give back. We give health
We don’t speak for others, but as a successful company, we think it’s important to give back to those who most need it.
And that’s why we’ve reached out in developing nations to help deliver healthcare that developed nations take for granted. This includes Eyes4Everest, the AusViet Charity Foundation, and helping Carmelite nuns in East Timor and the Wesleyan Mission to Bougainville.
November 20, 2025
AFT delivers 10th consecutive first half revenue increase
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today reports a strong first-half performance for the six months to 30 September 2025, with revenue growing 3…
September 25, 2025
On track for $300m FY27 revenue; positive iron IV study result
– Sales tracking in line with $300 million FY27 revenue target – Clinical trial supports the potential patient benefits of novel iron IV development …
May 26, 2025
AFT and Hikma extend US Maxigesic Cooperation
AFT Pharmaceuticals (NZX:AFT, ASX:AFP) today announces it has extended its US Maxigesic® licensing agreement with Hikma Pharmaceuticals….